05.08.20: Post Q2 Virtual Roadshow
Post Q2 Virtual RoadshowLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 5, 2020 Category: Pharmaceuticals Source Type: news

04.08.20: Second quarter of 2020:
Bayer: Solid performance despite COVID-19 impactEnsuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx & portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx & portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations - agreements in m...
Source: Bayer IR Newsfeed: Events - August 4, 2020 Category: Pharmaceuticals Source Type: news

04.08.20: Post Q2 Virtual Roadshow
Post Q2 Virtual RoadshowLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 4, 2020 Category: Pharmaceuticals Source Type: news

03.08.20: Bayer completes the sale of its Animal Health business unit to Elanco
Bayer completes the sale of its Animal Health business unit to Elancomehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 3, 2020 Category: Pharmaceuticals Source Type: news

04.08.20: Q2 2020 Investor Conference Call
Q2 2020 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 21, 2020 Category: Pharmaceuticals Source Type: news

21.07.20: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 21, 2020 Category: Pharmaceuticals Source Type: news

16.07.20: Not intended for U.S. and UK Media
U.S. FDA grants priority review to New Drug Application for vericiguat to treat chronic heart failuremehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 16, 2020 Category: Pharmaceuticals Source Type: news

09.07.20: Not intended for U.S. and UK Media
Bayer's finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetesFinerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care / Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events / Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized / Finerenone is the first investigational non-steroid...
Source: Bayer IR Newsfeed: Events - July 9, 2020 Category: Pharmaceuticals Source Type: news

08.07.20: Bayer remains committed to Roundup™ settlement
Bayer remains committed to Roundup™ settlementmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 8, 2020 Category: Pharmaceuticals Source Type: news

01.07.20: not for distribution in the united states of america, australia, canada, south africa or japan
Bayer issues new senior bonds with a volume of 6 billion eurosIssuance of four tranches with maturities between 4 and 12 years was substantially oversubscribedmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 2, 2020 Category: Pharmaceuticals Source Type: news

24.06.20: Bayer announces agreements to resolve major legacy Monsanto litigation
Bayer announces agreements to resolve major legacy Monsanto litigationCompany will make a total payment of $10.1 billion to $10.9 billion (?9.1 billion to ?9.8 billion) to resolve current and address potential future Roundup™ litigation / Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million / Funding sourced from free cash flow and Animal Health divestment / Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 25, 2020 Category: Pharmaceuticals Source Type: news

25.06.20: Investor Conference Call: Agreements to Resolve Major Legacy Monsanto Litigation
Investor Conference Call: Agreements to Resolve Major Legacy Monsanto LitigationLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 25, 2020 Category: Pharmaceuticals Source Type: news

19.06.20: Women empowerment in times of COVID-19
Bayer supports "The Challenge Initiative" of Johns Hopkins Bloomberg School of Public Health with 10 million USD"The Challenge Initiative" to scale up reproductive health for women and girls in urban poverty areas / Participating cities in East Africa, Francophone West Africa, Nigeria, and India / Integrate COVID-19 prevention and educationmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 19, 2020 Category: Pharmaceuticals Source Type: news

17.06.20: Bayer to Provide Crop Relief to Two Million Smallholder Farmers Impacted by COVID-19
Bayer to Provide Crop Relief to Two Million Smallholder Farmers Impacted by COVID-19Through its new "Better Farms, Better Lives" initiative, Bayer will complement its current commitment to support smallholder farmers in key countries by donating seeds and crop protection inputs / The donations help boost food security by supporting up to two million smallholder farmers facing increased challenges as a result of the on-going COVID-19 pandemicmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 17, 2020 Category: Pharmaceuticals Source Type: news

15.06.20: Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fractionFINEARTS-HF is the first large-scale, long-term study to investigate the non-steroidal, selective mineralocorticoid receptor antagonist finerenone on morbidity and mortality outcomes in a heart failure patient populationmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 16, 2020 Category: Pharmaceuticals Source Type: news

05.06.20: Not intended for U.S. and UK Media
Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failureRegulatory submissions based on positive data from Phase III VICTORIA study recently published in the New England Journal of Medicine (1)mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 5, 2020 Category: Pharmaceuticals Source Type: news

04.06.20: Deutsche Bank Virtual Access Berlin Conference 2020, Berlin, Germany
Deutsche Bank Virtual Access Berlin Conference 2020, Berlin, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 29, 2020 Category: Pharmaceuticals Source Type: news

29.05.20: Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program):
Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer71% overall response rate (ORR) per investigator assessment and median duration of response of 35.2 months shown in expanded data set of 116 adult patients with TRK fusion cancer / Among patients with brain metastases, ORR was also 71% / Majority of adverse events (AEs) were grade 1 or 2, no new unexpected grade 3 or 4 AEs were reported / New analysis demonstrates clinically meaningful and ...
Source: Bayer IR Newsfeed: Events - May 29, 2020 Category: Pharmaceuticals Source Type: news

22.05.20: Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 22, 2020 Category: Pharmaceuticals Source Type: news

19.05.20: Nine internationally recognized experts join Sustainability Council
Independent external council to advise Bayer's Board of Management on consistent implementation of its sustainability targetsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 19, 2020 Category: Pharmaceuticals Source Type: news

13.05.20: Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancerDarolutamide significantly reduced risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Darolutamide significantly delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE) / Darolutamide continues to demonstrate a favorable safety profile, with no new safety signals observed, even with a longer treatment duration, ...
Source: Bayer IR Newsfeed: Events - May 14, 2020 Category: Pharmaceuticals Source Type: news

11.05.20: Not intended for U.S. and UK Media
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific ProgramData on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Updated efficacy and safety data for larotrectinib (Vitrakvi®) from an expanded set of adult patients with TRK fusion cancer and a quality of life (QoL) analysis in adult and pediatric patients / New safety and efficacy data from established compounds including radium-223 dichloride (Xofigo®) and regorafenib (Stivarga®)mehr ...
Source: Bayer IR Newsfeed: Events - May 12, 2020 Category: Pharmaceuticals Source Type: news

06.05.20: Post Q1 Virtual Roadshow
Post Q1 Virtual RoadshowLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 6, 2020 Category: Pharmaceuticals Source Type: news

05.05.20: Post Q1 Virtual Roadshow
Post Q1 Virtual RoadshowLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 5, 2020 Category: Pharmaceuticals Source Type: news

14.05.20: BMO Global Farm to Market Virtual Conference, New York, U.S.A.
BMO Global Farm to Market Virtual Conference, New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news

18.05.20: Berenberg Virtual USA Conference 2020, Tarrytown, U.S.A.
Berenberg Virtual USA Conference 2020, Tarrytown, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news

19.05.20: Bernstein Agricultural Webinar, London, UK
Bernstein Agricultural Webinar, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news

19.05.20: Berenberg Virtual USA Conference 2020,Tarrytown, U.S.A.
Berenberg Virtual USA Conference 2020,Tarrytown, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news

19.05.20: UBS Virtual Global Healthcare Conference, New York, U.S.A.
UBS Virtual Global Healthcare Conference, New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news

28.04.20: CEO Werner Baumann at the Bayer AG Annual Stockholders' Meeting:
"We're active in the right businesses"Coronavirus crisis: Employee safety at the top of the agenda / First DAX company to hold virtual stockholders' meeting / Strategic and operational targets attained in 2019 / Dividend of 2.80 euros per share proposed / Good start to fiscal 2020 / Winkeljohann to succeed Wenning as Supervisory Board Chairmanmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 28, 2020 Category: Pharmaceuticals Source Type: news

27.04.20: First quarter of 2020:
Bayer: Good start to 2020 - activities marked by COVID-19Employee safety and business continuity are top priorities / Wide-ranging humanitarian and social engagement / Group sales increase by 6.0 percent (Fx & portfolio adj.) to 12.845 billion euros / EBITDA before special items up by 10.2 percent to 4.391 billion euros / All divisions report higher sales and earnings - strong demand at Consumer Health / Net income advances by 20.0 percent to 1.489 billion euros / Core earnings per share increase by 9.9 percent to 2.67 euros / Outlook for 2020: impact of COVID-19 not yet reliably quantifiablemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 27, 2020 Category: Pharmaceuticals Source Type: news

21.04.20: Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatmentsInvestigation of combination therapies including Bayer's chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) financial commitment and to supply products in support of the research / Plans to include more than 60 contributing research locations involving 6.000 patientsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 21, 2020 Category: Pharmaceuticals Source Type: news

20.04.20: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 20, 2020 Category: Pharmaceuticals Source Type: news

27.04.20: Q1 2020 Investor Conference Call
Q1 2020 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 14, 2020 Category: Pharmaceuticals Source Type: news

08.04.20: Not intended for U.S. and UK Media
Bayer launches pre-filled syringe to administer eye medication Eylea® in Europemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 8, 2020 Category: Pharmaceuticals Source Type: news

30.03.20: Not intended for U.S. and UK Media
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancerOral androgen receptor inhibitor (ARi) Nubeqa® (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profilemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 2, 2020 Category: Pharmaceuticals Source Type: news

29.03.20: Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:
Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgeryData from PRONOMOS study published in The New England Journal of Medicine and presented during a virtual session of the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual) / The first study to demonstrate that a Factor Xa inhibitor was superior to enoxaparin in reducing risk of major venous thromboembolism in adult patients who have undergone lower limb nonmajor orthopaedic surgery / Bleeding rates were low and not significantly different be...
Source: Bayer IR Newsfeed: Events - March 29, 2020 Category: Pharmaceuticals Source Type: news

28.03.20: Not intended for U.S. and UK Media - Data from Phase III VOYAGER PAD study published in The New England Journal of Medicine and presented during the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology
Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularizationThe only clinical outcome study to demonstrate the benefits of a combined antithrombotic and anti-platelet therapy in these vulnerable patients who currently have limited treatment options / Risk of acute limb ischemia was significantly reduced by 33% in these patients compared to those receiving aspirin alone / There was no significant increase in TIMI major bleeding, the principal safety outcome of the trialmehr ... (Source...
Source: Bayer IR Newsfeed: Events - March 28, 2020 Category: Pharmaceuticals Source Type: news

28.03.20: Not intended for U.S. and UK Media - Data from Phase III VICTORIA study presented at American College of Cardiology's 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)
Vericiguat significantly reduced the risk of the composite primary endpoint of cardiovascular death or heart failure hospitalizationVICTORIA is the first positive contemporary outcomes study focused exclusively on a chronic heart failure patient population following a worsening event / Treatment effect on the composite endpoint of cardiovascular death or heart failure hospitalization was consistently demonstrated regardless of background heart failure therapy / Vericiguat was well-tolerated - overall incidence rate of adverse events was comparable to placebo / Studied in a population with higher event rates than in other c...
Source: Bayer IR Newsfeed: Events - March 28, 2020 Category: Pharmaceuticals Source Type: news

27.03.20: Coronavirus pandemic:
Bayer planning to hold online-only stockholders' meeting on April 28, 2020Stockholders able to exercise right to submit questions and cast votes in a timely manner / Online stockholders' meeting enables proposed dividend of 2.80 euros per share for 2019 to be paid on time and in full / Baumann: "Reliability for our stockholders is very important, especially during the crisis"mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 27, 2020 Category: Pharmaceuticals Source Type: news

24.03.20: Bayer's due diligence procedures for M&A transactions are appropriate, special audit confirms
Bayer's due diligence procedures for M&A transactions are appropriate, special audit confirmsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 24, 2020 Category: Pharmaceuticals Source Type: news

20.03.20: Not intended for U.S. and UK Media - American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual):
Bayer announces five late-breaking presentations which include data from VICTORIA (vericiguat) and VOYAGER PAD (Xarelto™) Phase III studiesThe VICTORIA study provides insight into the efficacy of vericiguat, the first soluble guanylate cyclase (sGC) stimulator investigated in patients with chronic heart failure following a worsening event / The VOYAGER PAD study investigated the use of Xarelto 2.5 mg twice daily plus aspirin 100 mg once daily in patients with symptomatic peripheral artery disease (PAD) post peripheral revascularization / Five late-breaking abstracts have been accepted for presentation and demonstrate...
Source: Bayer IR Newsfeed: Events - March 20, 2020 Category: Pharmaceuticals Source Type: news

05.03.20: Roadshow Boston, U.S.A.
Roadshow Boston, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 5, 2020 Category: Pharmaceuticals Source Type: news

04.03.20: Roadshow New York, U.S.A.
Roadshow New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 4, 2020 Category: Pharmaceuticals Source Type: news

03.03.20: Roadshow New York, U.S.A.
Roadshow New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 3, 2020 Category: Pharmaceuticals Source Type: news

03.03.20: Roadshow London, UK
Roadshow London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 3, 2020 Category: Pharmaceuticals Source Type: news

02.03.20: Roadshow Edinburgh, Scotland
Roadshow Edinburgh, ScotlandLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 2, 2020 Category: Pharmaceuticals Source Type: news

25.02.21: Annual Report 2020
Annual Report 2020Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - February 27, 2020 Category: Pharmaceuticals Source Type: news

27.04.21: Annual StockholdersÂ’ Meeting 2021
Annual StockholdersÂ’ Meeting 2021Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - February 27, 2020 Category: Pharmaceuticals Source Type: news

12.05.21: Q1 2021 Quarterly Statement
Q1 2021 Quarterly StatementLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - February 27, 2020 Category: Pharmaceuticals Source Type: news